Pain Therapeutics (NASDAQ:PTIE)’s share price reached a new 52-week high during trading on Tuesday . The company traded as high as $2.84 and last traded at $2.78, with a volume of 804,487 shares traded. The stock had previously closed at $2.49.

A number of equities analysts have commented on PTIE shares. Zacks Investment Research raised shares of Pain Therapeutics from a “hold” rating to a “buy” rating and set a $2.75 price objective for the company in a research report on Saturday. Gabelli downgraded Pain Therapeutics from a “buy” rating to a “hold” rating and set a $2.50 target price for the company. in a report on Tuesday, September 13th.

The firm has a 50 day moving average price of $2.49 and a 200-day moving average price of $2.32. The stock’s market capitalization is $129.19 million.

This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/20/pain-therapeutics-ptie-sets-new-12-month-high-at-2-84.html

Pain Therapeutics (NASDAQ:PTIE) last issued its earnings results on Tuesday, July 19th. The biopharmaceutical company reported ($0.07) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.14) by $0.07. On average, analysts forecast that Pain Therapeutics will post ($0.46) EPS for the current fiscal year.

Large investors have recently added to or reduced their stakes in the stock. Gagnon Securities LLC raised its stake in Pain Therapeutics by 11.5% in the first quarter. Gagnon Securities LLC now owns 69,996 shares of the biopharmaceutical company’s stock worth $156,000 after buying an additional 7,197 shares during the last quarter. Brandes Investment Partners LP raised its stake in Pain Therapeutics by 108.8% in the second quarter. Brandes Investment Partners LP now owns 78,758 shares of the biopharmaceutical company’s stock worth $172,000 after buying an additional 41,039 shares during the last quarter. Acadian Asset Management LLC raised its stake in Pain Therapeutics by 0.7% in the second quarter. Acadian Asset Management LLC now owns 351,072 shares of the biopharmaceutical company’s stock worth $769,000 after buying an additional 2,471 shares during the last quarter. Bridgeway Capital Management Inc. raised its stake in Pain Therapeutics by 29.8% in the second quarter. Bridgeway Capital Management Inc. now owns 435,853 shares of the biopharmaceutical company’s stock worth $955,000 after buying an additional 100,000 shares during the last quarter. Finally, Renaissance Technologies LLC raised its stake in Pain Therapeutics by 8.1% in the first quarter. Renaissance Technologies LLC now owns 726,987 shares of the biopharmaceutical company’s stock worth $1,621,000 after buying an additional 54,200 shares during the last quarter. 55.07% of the stock is owned by institutional investors and hedge funds.

Pain Therapeutics Company Profile

Pain Therapeutics, Inc is a biopharmaceutical company. The Company is focused on drug development efforts on disorders of the nervous system, such as chronic pain. The Company’s lead drug candidate, REMOXY, is an abuse-deterrent, oral formulation of oxycodone (CII). The Company’s other products is FENROCK.

5 Day Chart for NASDAQ:PTIE

Receive News & Ratings for Pain Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pain Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.